MSM Found to Underestimate Risk of HIV Infection


Misperceptions about the risk of HIV infection should be corrected at the time of testing, with PrEP initiated same-day, if appropriate.

Jill Blumenthal, MD, associate clinical professor at the University of California, San Diego School of Medicine

Jill Blumenthal, MD, associate clinical professor at the University of California, San Diego School of Medicine

Jill Blumenthal, MD

In an oral abstract session at the 25th Conference for Retroviruses and Opportunistic Infections (CROI) held in Boston, Massachusetts, Jill Blumenthal, MD, associate clinical professor at the University of California, San Diego School of Medicine, explained how inaccurate HIV risk perception by men who have sex with men (MSM) remains an obstacle to prevention, despite greater access to pre-exposure prophylaxis (PrEP).

Although researchers continue to make great strides in the fight against HIV, there are still many obstacles to overcome in terms of prevention. One such obstacle is accurate HIV risk perception among MSM, a population accounting for 70% of new HIV infections in the US.

To address this issue, Blumenthal and her team studied whether or not providing information on their risk of contracting HIV to MSM would increase their uptake of PrEP.

The team tested the hypothesis in a randomized, controlled trial dubbed, PrEP Accessibility Research and Evaluation 2, or PrEPARE2, which enrolled 171 MSM participants, all recruited from HIV testing sites.

For the study, a baseline survey was given to participants that collected information like demographics, risk behaviors and the participant’s perception of their risk of contracting HIV. The results of the survey generated 2 risk scores: a self-perceived risk (SPR) score, which was based on 3 risk perception questions, and an HIV risk score (CalcR) which would calculate an individual’s estimated 1-year risk of becoming infected with HIV compared with the average risk among MSM.

According to the study abstract, the CalcR score was “based on reported condomless anal sex acts, sexually transmitted infections (STIs) and needle-sharing events.” Participants were categorized as either low, medium, high or very high risk for HIV, based on these scores.

Participants were then randomly assigned to 1 of 2 study arms: 86 were assigned to the intervention arm, where they were provided with their CalcR risk score; and 85 were assigned to the control arm, where they received standard counseling on reducing their risk of HIV infection only.

Of the 171 participants, 81% stated that they heard of PrEP and more than half (57%) professed feeling like they would be good candidates for PrEP. As a whole, participants reported a median of 5 sexual partners within the past 6 months.

After 8 weeks, investigators contacted participants in each group to see if they started PrEP or if they felt they were good candidates for the medication. The results revealed a total of 14 participants had begun PrEP out of a total of 135 participants who were contacted (59 from the control arm and 76 from the intervention arm).

Investigators found that 36% of the participants had low risk perception; 18% did not want to take pills; and 13% said that they were waiting for a PrEP visit. Additionally, further analysis revealed that participants’ SPR score did not line up with the CalcR score; more than one-third of the study participants underestimated their risk of HIV infection.

“In this cohort of at-risk MSM, providing an objective HIV risk score alone did not increase PrEP uptake, perhaps due to discordance between self-perceived and actual HIV risk,” study authors wrote. “Further, many participants did not think their risk was high enough to use PrEP.”

Based on the results of this study, when patients are being tested for HIV physicians should correct misunderstandings about the actual risk of the infection. Furthermore, PrEP should be introduced the same day in patients who are most at risk in order to improve uptake of the medication.

Click here to sign up for more MD Magazine content and updates.

Related Coverage >>>

Prioritizing HIV Transmission Clusters May Reduce Further Infections

Risk of Acquiring HIV Increases During and After Pregnancy, Research Suggests

The Quest to Cure HIV Through International Interdisciplinary Collaboration

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.